B.Riley initiated Abeona Therapeutics (ABEO +12.2%) with a Buy rating, PT $5 indicating a more than double upside from current levels.
Analyst Justin Zelin believes that the company is now positioned to potentially have three rare disease approvals by 2023.
https://seekingalpha.com/news/3615404-abeona-therapeutics-rallies-on-b-rileys-buy-rating
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.